Cambios longitudinales en el índice de ROX y el puntaje de HACOR en pacientes críticos con insuficiencia respiratoria aguda por COVID-19 que requirieron cánula nasal de alto flujo: estudio de cohorte retrospectivo
Cargando...
Fecha
2024
Título de la revista
ISSN de la revista
Título del volumen
Editor
Ediciones Universidad Simón Bolívar
Facultad de Ciencias de la Salud
Facultad de Ciencias de la Salud
Resumen
Introducción: Durante la pandemia de SARS-CoV-2, emergió la necesidad de
validar el uso de la Cánula Nasal de Alto Flujo (CNAF) y sus indicadores de éxito en
pacientes con Infecciones Respiratorias Agudas Graves (IRAG). Objetivo: evaluar
el impacto clínico del uso de la cánula nasal de alto flujo (CNAF) en pacientes con
insuficiencia respiratoria aguda hipoxémica moderada a severa debido a SARS
CoV-2, y validar la efectividad de los índices IROX, HACOR score en dos tiempos
críticos: al inicio del tratamiento y a las 24 horas, así como el delta de estos índices.
Materiales y métodos: Un estudio de cohorte retrospectivo. Se llevó a cabo en la
unidad de cuidados intensivos de una IPS en Cartagena, Colombia. Se incluyeron
en el estudio aquellos que cumplieron con los siguientes criterios de inclusión. Del
total de las historias revisadas, se excluyeron 41 de ellas porque no cumplían con
los criterios de inclusión. Finalmente, se analizaron un total de 115 pacientes. La
presente investigación es diseñada cumpliendo con los lineamientos éticos
establecidos en los documentos internacional y nacionalmente aceptados. Se
realizó un estudio retrospectivo con 115 pacientes, analizando el uso de CNAF y
evaluando estas herramientas y el delta al inicio y a las 24 horas de su uso.
Introduction: During the SARS-CoV-2 pandemic, the need emerged to validate the use of the High Flow Nasal Cannula (HFNC) and its success indicators in patients with Severe Acute Respiratory Infections (SARI). Objective: Our main objective was to evaluate the clinical impact of the use of highflow nasal cannula (HFNC) in patients with moderate to severe hypoxemic acute respiratory failure due to SARSCoV- 2, and to validate the effectiveness of the IROX, HACOR indices score at two critical times: at the beginning of treatment and at 24 hours as well as the delta of these indices. Materials and methods: A retrospective cohort study. It was carried out in the intensive care unit of an-IPS in Cartagena, Colombia. Those who met the following inclusion criteria were included in the study. Of the total stories reviewed, 41 were excluded because they did not meet the inclusion criteria. Finally, a total of 115 patients were analyzed. This research is designed in compliance with the ethical guidelines established in internationally and nationally accepted documents. A retrospective study was carried out with 115 patients, analyzing the use of HFNC and evaluating these tools and the delta at the beginning and 24 hours after their use.
Introduction: During the SARS-CoV-2 pandemic, the need emerged to validate the use of the High Flow Nasal Cannula (HFNC) and its success indicators in patients with Severe Acute Respiratory Infections (SARI). Objective: Our main objective was to evaluate the clinical impact of the use of highflow nasal cannula (HFNC) in patients with moderate to severe hypoxemic acute respiratory failure due to SARSCoV- 2, and to validate the effectiveness of the IROX, HACOR indices score at two critical times: at the beginning of treatment and at 24 hours as well as the delta of these indices. Materials and methods: A retrospective cohort study. It was carried out in the intensive care unit of an-IPS in Cartagena, Colombia. Those who met the following inclusion criteria were included in the study. Of the total stories reviewed, 41 were excluded because they did not meet the inclusion criteria. Finally, a total of 115 patients were analyzed. This research is designed in compliance with the ethical guidelines established in internationally and nationally accepted documents. A retrospective study was carried out with 115 patients, analyzing the use of HFNC and evaluating these tools and the delta at the beginning and 24 hours after their use.
Descripción
Palabras clave
Cánula nasal de alto flujo, SARS-CoV-2, Ventilación no invasiva, Insuficiencia Respiratoria Hipoxémica Aguda
